Drug Profile

MKK 900

Alternative Names: MKK-900; Recombinant non-adjuvanted respiratory syncytial virus vaccine - MAXVAX Biotechnology

Latest Information Update: 30 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MAXVAX Biotechnology
Class Protein vaccines; Respiratory syncytial virus vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Apr 2026 MAXVAX Biotechnology plans a phase I trial for Respiratory syncytial virus infections (Prevention) in Australia (IM, Injection) in April 2026 (NCT07492706)
25 Mar 2026 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (IM)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com